CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer
The microenvironment that surrounds pancreatic ductal adenocarcinoma (PDAC) is profoundly desmoplastic and immunosuppressive. Understanding triggers of immunosuppression during the process of pancreatic tumorigenesis would aid in establishing targets for effective prevention and therapy. Here, we in...
Saved in:
| Published in | Cancer research (Chicago, Ill.) Vol. 83; no. 7; pp. 1111 - 1127 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
American Association for Cancer Research
04.04.2023
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | The microenvironment that surrounds pancreatic ductal adenocarcinoma (PDAC) is profoundly desmoplastic and immunosuppressive. Understanding triggers of immunosuppression during the process of pancreatic tumorigenesis would aid in establishing targets for effective prevention and therapy. Here, we interrogated differential molecular mechanisms dependent on cell of origin and subtype that promote immunosuppression during PDAC initiation and in established tumors. Transcriptomic analysis of cell-of-origin-dependent epithelial gene signatures revealed that Nt5e/CD73, a cell-surface enzyme required for extracellular adenosine generation, is one of the top 10% of genes overexpressed in murine tumors arising from the ductal pancreatic epithelium as opposed to those rising from acinar cells. These findings were confirmed by IHC and high-performance liquid chromatography. Analysis in human PDAC subtypes indicated that high Nt5e in murine ductal PDAC models overlaps with high NT5E in human PDAC squamous and basal subtypes, considered to have the highest immunosuppression and worst prognosis. Multiplex immunofluorescent analysis showed that activated CD8+ T cells in the PDAC tumor microenvironment express high levels of CD73, indicating an opportunity for immunotherapeutic targeting. Delivery of CD73 small-molecule inhibitors through various delivery routes reduced tumor development and growth in genetically engineered and syngeneic mouse models. In addition, the adenosine receptor Adora2b was a determinant of adenosine-mediated immunosuppression in PDAC. These findings highlight a molecular trigger of the immunosuppressive PDAC microenvironment elevated in the ductal cell of origin, linking biology with subtype classification, critical components for PDAC immunoprevention and personalized approaches for immunotherapeutic intervention.
Ductal-derived pancreatic tumors have elevated epithelial and CD8+GZM+ T-cell CD73 expression that confers sensitivity to small-molecule inhibition of CD73 or Adora2b to promote CD8+ T-cell-mediated tumor regression. See related commentary by DelGiorno, p. 977. |
|---|---|
| AbstractList | Abstract
The microenvironment that surrounds pancreatic ductal adenocarcinoma (PDAC) is profoundly desmoplastic and immunosuppressive. Understanding triggers of immunosuppression during the process of pancreatic tumorigenesis would aid in establishing targets for effective prevention and therapy. Here, we interrogated differential molecular mechanisms dependent on cell of origin and subtype that promote immunosuppression during PDAC initiation and in established tumors. Transcriptomic analysis of cell-of-origin–dependent epithelial gene signatures revealed that Nt5e/CD73, a cell-surface enzyme required for extracellular adenosine generation, is one of the top 10% of genes overexpressed in murine tumors arising from the ductal pancreatic epithelium as opposed to those rising from acinar cells. These findings were confirmed by IHC and high-performance liquid chromatography. Analysis in human PDAC subtypes indicated that high Nt5e in murine ductal PDAC models overlaps with high NT5E in human PDAC squamous and basal subtypes, considered to have the highest immunosuppression and worst prognosis. Multiplex immunofluorescent analysis showed that activated CD8+ T cells in the PDAC tumor microenvironment express high levels of CD73, indicating an opportunity for immunotherapeutic targeting. Delivery of CD73 small-molecule inhibitors through various delivery routes reduced tumor development and growth in genetically engineered and syngeneic mouse models. In addition, the adenosine receptor Adora2b was a determinant of adenosine-mediated immunosuppression in PDAC. These findings highlight a molecular trigger of the immunosuppressive PDAC microenvironment elevated in the ductal cell of origin, linking biology with subtype classification, critical components for PDAC immunoprevention and personalized approaches for immunotherapeutic intervention.
Significance:
Ductal-derived pancreatic tumors have elevated epithelial and CD8+GZM+ T-cell CD73 expression that confers sensitivity to small-molecule inhibition of CD73 or Adora2b to promote CD8+ T-cell–mediated tumor regression.
See related commentary by DelGiorno, p. 977 The microenvironment that surrounds pancreatic ductal adenocarcinoma (PDAC) is profoundly desmoplastic and immunosuppressive. Understanding triggers of immunosuppression during the process of pancreatic tumorigenesis would aid in establishing targets for effective prevention and therapy. Here, we interrogated differential molecular mechanisms dependent on cell of origin and subtype that promote immunosuppression during PDAC initiation and in established tumors. Transcriptomic analysis of cell-of-origin-dependent epithelial gene signatures revealed that Nt5e/CD73, a cell-surface enzyme required for extracellular adenosine generation, is one of the top 10% of genes overexpressed in murine tumors arising from the ductal pancreatic epithelium as opposed to those rising from acinar cells. These findings were confirmed by IHC and high-performance liquid chromatography. Analysis in human PDAC subtypes indicated that high Nt5e in murine ductal PDAC models overlaps with high NT5E in human PDAC squamous and basal subtypes, considered to have the highest immunosuppression and worst prognosis. Multiplex immunofluorescent analysis showed that activated CD8+ T cells in the PDAC tumor microenvironment express high levels of CD73, indicating an opportunity for immunotherapeutic targeting. Delivery of CD73 small-molecule inhibitors through various delivery routes reduced tumor development and growth in genetically engineered and syngeneic mouse models. In addition, the adenosine receptor Adora2b was a determinant of adenosine-mediated immunosuppression in PDAC. These findings highlight a molecular trigger of the immunosuppressive PDAC microenvironment elevated in the ductal cell of origin, linking biology with subtype classification, critical components for PDAC immunoprevention and personalized approaches for immunotherapeutic intervention.The microenvironment that surrounds pancreatic ductal adenocarcinoma (PDAC) is profoundly desmoplastic and immunosuppressive. Understanding triggers of immunosuppression during the process of pancreatic tumorigenesis would aid in establishing targets for effective prevention and therapy. Here, we interrogated differential molecular mechanisms dependent on cell of origin and subtype that promote immunosuppression during PDAC initiation and in established tumors. Transcriptomic analysis of cell-of-origin-dependent epithelial gene signatures revealed that Nt5e/CD73, a cell-surface enzyme required for extracellular adenosine generation, is one of the top 10% of genes overexpressed in murine tumors arising from the ductal pancreatic epithelium as opposed to those rising from acinar cells. These findings were confirmed by IHC and high-performance liquid chromatography. Analysis in human PDAC subtypes indicated that high Nt5e in murine ductal PDAC models overlaps with high NT5E in human PDAC squamous and basal subtypes, considered to have the highest immunosuppression and worst prognosis. Multiplex immunofluorescent analysis showed that activated CD8+ T cells in the PDAC tumor microenvironment express high levels of CD73, indicating an opportunity for immunotherapeutic targeting. Delivery of CD73 small-molecule inhibitors through various delivery routes reduced tumor development and growth in genetically engineered and syngeneic mouse models. In addition, the adenosine receptor Adora2b was a determinant of adenosine-mediated immunosuppression in PDAC. These findings highlight a molecular trigger of the immunosuppressive PDAC microenvironment elevated in the ductal cell of origin, linking biology with subtype classification, critical components for PDAC immunoprevention and personalized approaches for immunotherapeutic intervention.Ductal-derived pancreatic tumors have elevated epithelial and CD8+GZM+ T-cell CD73 expression that confers sensitivity to small-molecule inhibition of CD73 or Adora2b to promote CD8+ T-cell-mediated tumor regression. See related commentary by DelGiorno, p. 977.SIGNIFICANCEDuctal-derived pancreatic tumors have elevated epithelial and CD8+GZM+ T-cell CD73 expression that confers sensitivity to small-molecule inhibition of CD73 or Adora2b to promote CD8+ T-cell-mediated tumor regression. See related commentary by DelGiorno, p. 977. Ductal-derived pancreatic tumors have elevated epithelial and CD8 + GZM + T-cell CD73 expression that confers sensitivity to small-molecule inhibition of CD73 or Adora2b to promote CD8 + T-cell–mediated tumor regression. The microenvironment that surrounds pancreatic ductal adenocarcinoma (PDAC) is profoundly desmoplastic and immunosuppressive. Understanding triggers of immunosuppression during the process of pancreatic tumorigenesis would aid in establishing targets for effective prevention and therapy. Here, we interrogated differential molecular mechanisms dependent on cell of origin and subtype that promote immunosuppression during PDAC initiation and in established tumors. Transcriptomic analysis of cell-of-origin–dependent epithelial gene signatures revealed that Nt5e/CD73, a cell-surface enzyme required for extracellular adenosine generation, is one of the top 10% of genes overexpressed in murine tumors arising from the ductal pancreatic epithelium as opposed to those rising from acinar cells. These findings were confirmed by IHC and high-performance liquid chromatography. Analysis in human PDAC subtypes indicated that high Nt5e in murine ductal PDAC models overlaps with high NT5E in human PDAC squamous and basal subtypes, considered to have the highest immunosuppression and worst prognosis. Multiplex immunofluorescent analysis showed that activated CD8 + T cells in the PDAC tumor microenvironment express high levels of CD73, indicating an opportunity for immunotherapeutic targeting. Delivery of CD73 small-molecule inhibitors through various delivery routes reduced tumor development and growth in genetically engineered and syngeneic mouse models. In addition, the adenosine receptor Adora2b was a determinant of adenosine-mediated immunosuppression in PDAC. These findings highlight a molecular trigger of the immunosuppressive PDAC microenvironment elevated in the ductal cell of origin, linking biology with subtype classification, critical components for PDAC immunoprevention and personalized approaches for immunotherapeutic intervention. The microenvironment that surrounds pancreatic ductal adenocarcinoma (PDAC) is profoundly desmoplastic and immunosuppressive. Understanding triggers of immunosuppression during the process of pancreatic tumorigenesis would aid in establishing targets for effective prevention and therapy. Here, we interrogated differential molecular mechanisms dependent on cell of origin and subtype that promote immunosuppression during PDAC initiation and in established tumors. Transcriptomic analysis of cell-of-origin-dependent epithelial gene signatures revealed that Nt5e/CD73, a cell-surface enzyme required for extracellular adenosine generation, is one of the top 10% of genes overexpressed in murine tumors arising from the ductal pancreatic epithelium as opposed to those rising from acinar cells. These findings were confirmed by IHC and high-performance liquid chromatography. Analysis in human PDAC subtypes indicated that high Nt5e in murine ductal PDAC models overlaps with high NT5E in human PDAC squamous and basal subtypes, considered to have the highest immunosuppression and worst prognosis. Multiplex immunofluorescent analysis showed that activated CD8+ T cells in the PDAC tumor microenvironment express high levels of CD73, indicating an opportunity for immunotherapeutic targeting. Delivery of CD73 small-molecule inhibitors through various delivery routes reduced tumor development and growth in genetically engineered and syngeneic mouse models. In addition, the adenosine receptor Adora2b was a determinant of adenosine-mediated immunosuppression in PDAC. These findings highlight a molecular trigger of the immunosuppressive PDAC microenvironment elevated in the ductal cell of origin, linking biology with subtype classification, critical components for PDAC immunoprevention and personalized approaches for immunotherapeutic intervention. Ductal-derived pancreatic tumors have elevated epithelial and CD8+GZM+ T-cell CD73 expression that confers sensitivity to small-molecule inhibition of CD73 or Adora2b to promote CD8+ T-cell-mediated tumor regression. See related commentary by DelGiorno, p. 977. |
| Author | Mohammed, Altaf Strickland, Lincoln N Pruski, Melissa Chandra, Vidhi Savage, Michelle I Le Roux, Olivereen Sahin, Ismet Vucic, Emily Sei, Shizuko Brown, Powel H Eltzschig, Holger K McAllister, Florencia Bynon, John S Bar-Sagi, Dafna Thosani, Nirav C Wray, Curtis J Dai, Yulin Faraoni, Erika Y Li, Le Mills, Tingting Zhao, Zhongming Bailey-Lundberg, Jennifer M Singh, Kanchan Clark, Trent Van Buren, George Poulsen, Kyle L Warner, Amanda N Vornik, Lana A O'Brien, Baylee J |
| AuthorAffiliation | 5 Department of Engineering, Texas Southern University, Houston, Texas 6 Departments of Biochemistry and Molecular Pharmacology and Medicine, NYU Langone School of Medicine, New York, New York 8 Division of Surgical Oncology, Baylor College of Medicine, Houston, Texas 11 Center for Perioperative Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, Texas 2 Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas 4 Center for Precision Health, School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, Texas 12 Division of Cancer Prevention, National Cancer Institute, Rockville, Maryland 13 Department of Biochemistry, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, Texas 7 Division of Gastroenterology, Hepatology, and Nutrition, Department of Internal Medicine, McGovern Medical School, The University of Texas Heal |
| AuthorAffiliation_xml | – name: 5 Department of Engineering, Texas Southern University, Houston, Texas – name: 7 Division of Gastroenterology, Hepatology, and Nutrition, Department of Internal Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, Texas – name: 10 Department of Surgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, Texas – name: 8 Division of Surgical Oncology, Baylor College of Medicine, Houston, Texas – name: 14 Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas – name: 1 Department of Anesthesiology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, Texas – name: 13 Department of Biochemistry, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, Texas – name: 6 Departments of Biochemistry and Molecular Pharmacology and Medicine, NYU Langone School of Medicine, New York, New York – name: 3 The Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center, and The University of Texas Health Science Center at Houston, Houston, Texas – name: 11 Center for Perioperative Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, Texas – name: 9 Center for Interventional Gastroenterology at UTHealth (iGUT), McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, Texas – name: 12 Division of Cancer Prevention, National Cancer Institute, Rockville, Maryland – name: 15 Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas – name: 2 Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas – name: 4 Center for Precision Health, School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, Texas |
| Author_xml | – sequence: 1 givenname: Erika Y orcidid: 0000-0003-0731-2122 surname: Faraoni fullname: Faraoni, Erika Y organization: Department of Anesthesiology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, Texas – sequence: 2 givenname: Kanchan orcidid: 0000-0002-7140-434X surname: Singh fullname: Singh, Kanchan organization: Department of Anesthesiology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, Texas – sequence: 3 givenname: Vidhi orcidid: 0000-0003-3642-2144 surname: Chandra fullname: Chandra, Vidhi organization: The Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center, and The University of Texas Health Science Center at Houston, Houston, Texas – sequence: 4 givenname: Olivereen orcidid: 0000-0003-1882-879X surname: Le Roux fullname: Le Roux, Olivereen organization: Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas – sequence: 5 givenname: Yulin orcidid: 0000-0003-1874-7893 surname: Dai fullname: Dai, Yulin organization: Center for Precision Health, School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, Texas – sequence: 6 givenname: Ismet orcidid: 0000-0002-1081-8231 surname: Sahin fullname: Sahin, Ismet organization: Department of Engineering, Texas Southern University, Houston, Texas – sequence: 7 givenname: Baylee J orcidid: 0000-0003-4272-6654 surname: O'Brien fullname: O'Brien, Baylee J organization: Department of Anesthesiology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, Texas – sequence: 8 givenname: Lincoln N orcidid: 0000-0002-2347-4431 surname: Strickland fullname: Strickland, Lincoln N organization: Department of Anesthesiology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, Texas – sequence: 9 givenname: Le orcidid: 0000-0002-5610-2343 surname: Li fullname: Li, Le organization: Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas – sequence: 10 givenname: Emily orcidid: 0000-0002-2879-2455 surname: Vucic fullname: Vucic, Emily organization: Departments of Biochemistry and Molecular Pharmacology and Medicine, NYU Langone School of Medicine, New York, New York – sequence: 11 givenname: Amanda N orcidid: 0000-0002-4616-089X surname: Warner fullname: Warner, Amanda N organization: The Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center, and The University of Texas Health Science Center at Houston, Houston, Texas – sequence: 12 givenname: Melissa orcidid: 0000-0001-8015-5835 surname: Pruski fullname: Pruski, Melissa organization: Division of Gastroenterology, Hepatology, and Nutrition, Department of Internal Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, Texas – sequence: 13 givenname: Trent orcidid: 0000-0002-6499-4564 surname: Clark fullname: Clark, Trent organization: Department of Anesthesiology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, Texas – sequence: 14 givenname: George orcidid: 0000-0001-7637-3717 surname: Van Buren fullname: Van Buren, George organization: Division of Surgical Oncology, Baylor College of Medicine, Houston, Texas – sequence: 15 givenname: Nirav C orcidid: 0000-0002-4607-6241 surname: Thosani fullname: Thosani, Nirav C organization: Center for Interventional Gastroenterology at UTHealth (iGUT), McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, Texas – sequence: 16 givenname: John S orcidid: 0000-0003-2196-0812 surname: Bynon fullname: Bynon, John S organization: Department of Surgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, Texas – sequence: 17 givenname: Curtis J orcidid: 0000-0003-4425-4566 surname: Wray fullname: Wray, Curtis J organization: Department of Surgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, Texas – sequence: 18 givenname: Dafna orcidid: 0000-0003-2597-8948 surname: Bar-Sagi fullname: Bar-Sagi, Dafna organization: Department of Engineering, Texas Southern University, Houston, Texas – sequence: 19 givenname: Kyle L orcidid: 0000-0003-3218-8418 surname: Poulsen fullname: Poulsen, Kyle L organization: Center for Perioperative Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, Texas – sequence: 20 givenname: Lana A orcidid: 0000-0002-1812-0305 surname: Vornik fullname: Vornik, Lana A organization: Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas – sequence: 21 givenname: Michelle I orcidid: 0000-0003-4927-9471 surname: Savage fullname: Savage, Michelle I organization: Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas – sequence: 22 givenname: Shizuko orcidid: 0000-0002-4822-6602 surname: Sei fullname: Sei, Shizuko organization: Division of Cancer Prevention, National Cancer Institute, Rockville, Maryland – sequence: 23 givenname: Altaf orcidid: 0000-0003-1058-6909 surname: Mohammed fullname: Mohammed, Altaf organization: Division of Cancer Prevention, National Cancer Institute, Rockville, Maryland – sequence: 24 givenname: Zhongming orcidid: 0000-0002-3477-0914 surname: Zhao fullname: Zhao, Zhongming organization: Center for Precision Health, School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, Texas – sequence: 25 givenname: Powel H orcidid: 0000-0002-3398-163X surname: Brown fullname: Brown, Powel H organization: Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas – sequence: 26 givenname: Tingting orcidid: 0000-0002-6041-4788 surname: Mills fullname: Mills, Tingting organization: Department of Biochemistry, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, Texas – sequence: 27 givenname: Holger K orcidid: 0000-0002-5676-6473 surname: Eltzschig fullname: Eltzschig, Holger K organization: Center for Perioperative Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, Texas – sequence: 28 givenname: Florencia orcidid: 0000-0002-9915-0943 surname: McAllister fullname: McAllister, Florencia organization: Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas – sequence: 29 givenname: Jennifer M orcidid: 0000-0002-4750-106X surname: Bailey-Lundberg fullname: Bailey-Lundberg, Jennifer M organization: Center for Perioperative Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, Texas |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36720042$$D View this record in MEDLINE/PubMed |
| BookMark | eNpVkU1v2zAMhoUhw5K0-wkrdNzFqT4j51QEzrYWKNYCW8-CLDOOBlvyJDtA__0UtAvaC0WCL19SeJZo5oMHhL5QsqJUlteEkLKQQrFVtf1ZMFYwKfkHtKCSl4USQs7Q4qyZo2VKf3IpKZGf0JyvFSNEsAVqq53ixQ4G8A34EW9zDMl5wL9c603nfIvHQwxTe8i9EA2r8S66IyR81_dT1k7DECElFzx2Hu8mO5oOPxpvI5jRWVzlFOIl-rg3XYLPr-8Fevr-7Xd1W9w__LirtveFFZSNhVSW1HYPxDaQD2xUbRVvWGm4BCV4XdYNZbksZcmpNZsGakq42HO-5mxDCL9ANy--w1T30Nj8p2g6PUTXm_isg3H6fce7g27DUVNCFC3pJjt8fXWI4e8EadS9Sxa6zngIU9JMKbrmayFYlsoXqY0hpQj78x5K9ImSPhHQJwI6U9KM6ROlPHf19sjz1H8s_B-ZAZDb |
| CitedBy_id | crossref_primary_10_1016_j_medj_2023_09_005 crossref_primary_10_1186_s12951_024_02643_w crossref_primary_10_1186_s12967_023_04702_6 crossref_primary_10_3390_ijms241411759 crossref_primary_10_3389_fimmu_2023_1130358 crossref_primary_10_1038_s41368_024_00308_w crossref_primary_10_1016_j_wneu_2023_12_051 crossref_primary_10_1038_s41467_024_45097_2 crossref_primary_10_3389_fimmu_2024_1434118 crossref_primary_10_3390_biom13091387 |
| Cites_doi | 10.1530/JOE-11-0434 10.1007/978-1-0716-2014-4_8 10.1001/jamaoncol.2022.2319 10.1016/j.celrep.2021.109981 10.1038/s41374-020-00490-5 10.1096/fj.202201537R 10.1007/s00109-018-01742-0 10.1186/s40425-018-0441-8 10.1038/s41467-021-26134-w 10.1002/tera.1420450109 10.1080/2162402X.2016.1208875 10.1681/ASN.2006101141 10.1016/j.ccell.2021.07.007 10.1093/nar/gkz401 10.3389/fonc.2022.995027 10.1016/j.pan.2021.03.018 10.1093/bioinformatics/bts635 10.1158/0008-5472.CAN-06-3752 10.1186/s12943-017-0665-0 10.1172/JCI114064 10.1038/s41467-018-08123-8 10.1038/nm1617 10.1038/nature16965 10.1038/onc.2015.441 10.1101/pdb.prot078279 10.1158/2159-8290.CD-20-0633 10.1038/nm.2344 10.1038/nature13085 10.1053/j.gastro.2009.05.052 10.1084/jem.20190354 10.1158/2326-6066.CIR-22-0260 10.1016/j.ccell.2017.07.007 10.1158/0008-5472.CAN-06-3822 10.1007/s00262-018-2290-1 10.1038/s41575-020-0300-1 10.1186/1471-2105-14-7 10.1152/jappl.1989.66.2.901 10.1158/0008-5472.CAN-13-3583 10.3389/fphys.2022.849258 10.1172/JCI0215337 10.1158/2326-6066.CIR-19-0833 10.1186/gb-2010-11-10-r106 10.3390/ijms19123837 10.1038/s41388-021-02132-6 10.1158/2159-8290.CD-NB2021-0313 10.1080/2162402X.2020.1744946 |
| ContentType | Journal Article |
| Copyright | 2023 The Authors; Published by the American Association for Cancer Research. 2023 The Authors; Published by the American Association for Cancer Research 2023 American Association for Cancer Research |
| Copyright_xml | – notice: 2023 The Authors; Published by the American Association for Cancer Research. – notice: 2023 The Authors; Published by the American Association for Cancer Research 2023 American Association for Cancer Research |
| DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 5PM |
| DOI | 10.1158/0008-5472.CAN-22-2553 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
| DatabaseTitleList | CrossRef MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| DocumentTitleAlternate | CD73/Adora2b Signaling Drives Immunosuppression in Ductal PDAC |
| EISSN | 1538-7445 |
| EndPage | 1127 |
| ExternalDocumentID | 10_1158_0008_5472_CAN_22_2553 36720042 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NIDDK NIH HHS grantid: R01 DK122796 – fundername: CLC NIH HHS grantid: 75N90019D00021 – fundername: NHLBI NIH HHS grantid: R01 HL133900 – fundername: NCI NIH HHS grantid: P30 CA125123 – fundername: NLM NIH HHS grantid: R01 LM012806 – fundername: ORFDO NIH HHS grantid: 75N99019D00021 – fundername: NIDDK NIH HHS grantid: P30 DK056338 – fundername: NHLBI NIH HHS grantid: R01 HL154720 – fundername: NIGMS NIH HHS grantid: T32 GM135118 – fundername: NCI NIH HHS grantid: R21 CA249924 – fundername: ; grantid: NCI R37 CA237384 – fundername: ; grantid: R01HL133900 – fundername: ; grantid: RP180734 – fundername: ; grantid: 11-70-25-BAIL – fundername: ; grantid: Translational Award – fundername: ; grantid: CA125123 – fundername: ; grantid: 75N91019D00021 – fundername: ; grantid: RP180672 – fundername: ; grantid: R01DK122796 – fundername: ; grantid: RP200173 |
| GroupedDBID | --- -ET 18M 29B 2WC 34G 39C 476 53G 5GY 5RE 5VS 6J9 ABOCM ACGFO ACIWK ACPRK ACSVP ADBBV ADNWM AENEX AFHIN AFOSN AFRAH ALMA_UNASSIGNED_HOLDINGS BAWUL BTFSW CGR CS3 CUY CVF DIK DU5 EBS ECM EIF EJD F5P FRP GX1 IH2 KQ8 L7B LSO NPM OK1 P0W P2P PQQKQ RCR RHF RHI RNS SJN TR2 W2D W8F WH7 WOQ YKV YZZ AAYXX CITATION 7X8 AETEA 5PM |
| ID | FETCH-LOGICAL-c412t-57c0bcfe0cde004d7bc73d28a35e743b8bd1228a85831ca9deb1034f336329003 |
| ISSN | 0008-5472 1538-7445 |
| IngestDate | Tue Sep 17 21:32:51 EDT 2024 Sat Aug 17 04:44:54 EDT 2024 Thu Sep 26 16:54:37 EDT 2024 Wed Oct 02 05:28:03 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 7 |
| Language | English |
| License | 2023 The Authors; Published by the American Association for Cancer Research. This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c412t-57c0bcfe0cde004d7bc73d28a35e743b8bd1228a85831ca9deb1034f336329003 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 E.Y. Faraoni and K. Singh contributed equally to this article. Cancer Res 2023;83:1111–27 |
| ORCID | 0000-0002-4607-6241 0000-0003-2196-0812 0000-0001-8015-5835 0000-0002-4822-6602 0000-0002-2879-2455 0000-0002-4750-106X 0000-0002-3398-163X 0000-0002-1081-8231 0000-0002-5610-2343 0000-0003-4425-4566 0000-0002-5676-6473 0000-0002-7140-434X 0000-0002-9915-0943 0000-0002-6499-4564 0000-0003-1874-7893 0000-0003-2597-8948 0000-0003-0731-2122 0000-0002-4616-089X 0000-0002-2347-4431 0000-0001-7637-3717 0000-0003-3218-8418 0000-0003-1058-6909 0000-0003-1882-879X 0000-0002-1812-0305 0000-0003-4927-9471 0000-0002-6041-4788 0000-0002-3477-0914 0000-0003-4272-6654 0000-0003-3642-2144 |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC10071819 |
| PMID | 36720042 |
| PQID | 2771636442 |
| PQPubID | 23479 |
| PageCount | 17 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_10071819 proquest_miscellaneous_2771636442 crossref_primary_10_1158_0008_5472_CAN_22_2553 pubmed_primary_36720042 |
| PublicationCentury | 2000 |
| PublicationDate | 2023-04-04 |
| PublicationDateYYYYMMDD | 2023-04-04 |
| PublicationDate_xml | – month: 04 year: 2023 text: 2023-04-04 day: 04 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Cancer research (Chicago, Ill.) |
| PublicationTitleAlternate | Cancer Res |
| PublicationYear | 2023 |
| Publisher | American Association for Cancer Research |
| Publisher_xml | – name: American Association for Cancer Research |
| References | 37014046 - Cancer Res. 2023 Apr 4;83(7):977-978. doi: 10.1158/0008-5472.CAN-23-0268 Chen (2023040500033409300_) 2019; 10 Shevchenko (2023040500033409300_) 2020; 9 Synnestvedt (2023040500033409300_) 2002; 110 Warburton (2023040500033409300_) 1989; 66 Cekic (2023040500033409300_) 2014; 74 Anders (2023040500033409300_) 2010; 11 Idzko (2023040500033409300_) 2007; 13 Faraoni (2023040500033409300_) 2022; 12 Faraoni (2023040500033409300_) 2022; 13 Collisson (2023040500033409300_) 2011; 17 Ma (2023040500033409300_) 2017; 16 Mehrara (2023040500033409300_) 2007; 67 Cancer Genome Atlas Research Network (2023040500033409300_) 2017; 32 Freed-Pastor (2023040500033409300_) 2021; 39 Sek (2023040500033409300_) 2018; 19 Bailey (2023040500033409300_) 2016; 531 Sciarra (2023040500033409300_) 2019; 68 Liao (2023040500033409300_) 2019; 47 Reichert (2023040500033409300_) 2015; 2015 Jacoberger-Foissac (2023040500033409300_) 2023; 11 Hay (2023040500033409300_) 2016; 5 King (2023040500033409300_) 2022; 41 Hänzelmann (2023040500033409300_) 2013; 14 Cowen (2023040500033409300_) 1989; 83 (2023040500033409300_) 2021; 11 Schneider (2023040500033409300_) 2021; 12 O'Brien (2023040500033409300_) 2023; 37 Quesada (2023040500033409300_) 2022; 2435 Dobin (2023040500033409300_) 2013; 29 Singh (2023040500033409300_) 2021; 101 Campbell (2023040500033409300_) 2007; 67 Wang (2023040500033409300_) 2018; 6 Katz (2023040500033409300_) 2022; 8 Burnstock (2023040500033409300_) 2012; 213 Zhang (2023040500033409300_) 2020; 217 Ji (2023040500033409300_) 2009; 137 Chen (2023040500033409300_) 2020; 8 Zhou (2023040500033409300_) 2019; 97 Grenz (2023040500033409300_) 2007; 18 Knudsen (2023040500033409300_) 1992; 45 Nowicka (2023040500033409300_) 2017 Zhao (2023040500033409300_) 2021; 21 Hosein (2023040500033409300_) 2020; 17 Flowers (2023040500033409300_) 2021; 11 Bailey (2023040500033409300_) 2016; 35 Idzko (2023040500033409300_) 2014; 509 Fang (2023040500033409300_) 2021; 37 |
| References_xml | – volume: 213 start-page: 123 year: 2012 ident: 2023040500033409300_ article-title: Purinergic signalling in the pancreas in health and disease publication-title: J Endocrinol doi: 10.1530/JOE-11-0434 contributor: fullname: Burnstock – volume: 2435 start-page: 107 year: 2022 ident: 2023040500033409300_ article-title: Assessment of the murine tumor microenvironment by multiplex immunofluorescence publication-title: Methods Mol Biol doi: 10.1007/978-1-0716-2014-4_8 contributor: fullname: Quesada – volume: 8 start-page: 1263 year: 2022 ident: 2023040500033409300_ article-title: Efficacy of preoperative mFOLFIRINOX vs mFOLFIRINOX plus hypofractionated radiotherapy for borderline resectable adenocarcinoma of the pancreas: the A021501 phase 2 randomized clinical trial publication-title: JAMA Oncol doi: 10.1001/jamaoncol.2022.2319 contributor: fullname: Katz – volume: 37 start-page: 109981 year: 2021 ident: 2023040500033409300_ article-title: The cell-surface 5'-nucleotidase CD73 defines a functional T memory cell subset that declines with age publication-title: Cell Rep doi: 10.1016/j.celrep.2021.109981 contributor: fullname: Fang – volume: 101 start-page: 177 year: 2021 ident: 2023040500033409300_ article-title: Kras mutation rate precisely orchestrates ductal derived pancreatic intraepithelial neoplasia and pancreatic cancer publication-title: Lab Invest doi: 10.1038/s41374-020-00490-5 contributor: fullname: Singh – volume: 37 start-page: e22684 year: 2023 ident: 2023040500033409300_ article-title: CD73-generated extracellular adenosine promotes resolution of neutrophil-mediated tissue injury and restrains metaplasia in pancreatitis publication-title: FASEB J doi: 10.1096/fj.202201537R contributor: fullname: O'Brien – volume: 97 start-page: 803 year: 2019 ident: 2023040500033409300_ article-title: The distinct role of CD73 in the progression of pancreatic cancer publication-title: J Mol Med (Berl) doi: 10.1007/s00109-018-01742-0 contributor: fullname: Zhou – volume: 6 start-page: 136 year: 2018 ident: 2023040500033409300_ article-title: Purinergic targeting enhances immunotherapy of CD73 publication-title: J Immunother Cancer doi: 10.1186/s40425-018-0441-8 contributor: fullname: Wang – volume: 12 start-page: 5911 year: 2021 ident: 2023040500033409300_ article-title: CD73-mediated adenosine production by CD8 T cell-derived extracellular vesicles constitutes an intrinsic mechanism of immune suppression publication-title: Nat Commun doi: 10.1038/s41467-021-26134-w contributor: fullname: Schneider – volume: 45 start-page: 91 year: 1992 ident: 2023040500033409300_ article-title: Effects of (R)-deoxycoformycin (pentostatin) on intrauterine nucleoside catabolism and embryo viability in the pregnant mouse publication-title: Teratology doi: 10.1002/tera.1420450109 contributor: fullname: Knudsen – volume: 5 start-page: e1208875 year: 2016 ident: 2023040500033409300_ article-title: Targeting CD73 in the tumor microenvironment with MEDI9447 publication-title: Oncoimmunology doi: 10.1080/2162402X.2016.1208875 contributor: fullname: Hay – volume: 18 start-page: 833 year: 2007 ident: 2023040500033409300_ article-title: Protective role of ecto-5'-nucleotidase (CD73) in renal ischemia publication-title: J Am Soc Nephrol doi: 10.1681/ASN.2006101141 contributor: fullname: Grenz – volume: 39 start-page: 1342 year: 2021 ident: 2023040500033409300_ article-title: The CD155/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer publication-title: Cancer Cell doi: 10.1016/j.ccell.2021.07.007 contributor: fullname: Freed-Pastor – volume: 47 start-page: W199 year: 2019 ident: 2023040500033409300_ article-title: 2019: gene set analysis toolkit with revamped UIs and APIs publication-title: Nucleic Acids Res doi: 10.1093/nar/gkz401 contributor: fullname: Liao – volume: 12 start-page: 995027 year: 2022 ident: 2023040500033409300_ article-title: Radiofrequency ablation in combination with CD73 inhibitor AB680 reduces tumor growth and enhances anti-tumor immunity in a syngeneic model of pancreatic ductal adenocarcinoma publication-title: Front Oncol doi: 10.3389/fonc.2022.995027 contributor: fullname: Faraoni – volume: 21 start-page: 942 year: 2021 ident: 2023040500033409300_ article-title: Overexpression of CD73 in pancreatic ductal adenocarcinoma is associated with immunosuppressive tumor microenvironment and poor survival publication-title: Pancreatology doi: 10.1016/j.pan.2021.03.018 contributor: fullname: Zhao – volume: 29 start-page: 15 year: 2013 ident: 2023040500033409300_ article-title: STAR: ultrafast universal RNA-seq aligner publication-title: Bioinformatics doi: 10.1093/bioinformatics/bts635 contributor: fullname: Dobin – volume: 67 start-page: 2098 year: 2007 ident: 2023040500033409300_ article-title: K-Ras promotes growth transformation and invasion of immortalized human pancreatic cells by Raf and phosphatidylinositol 3-kinase signaling publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-06-3752 contributor: fullname: Campbell – volume: 16 start-page: 99 year: 2017 ident: 2023040500033409300_ article-title: Blockade of adenosine A2A receptor enhances CD8 publication-title: Mol Cancer doi: 10.1186/s12943-017-0665-0 contributor: fullname: Ma – volume: 83 start-page: 1651 year: 1989 ident: 2023040500033409300_ article-title: Extracellular adenosine triphosphate activates calcium mobilization in human phagocytic leukocytes and neutrophil/monocyte progenitor cells publication-title: J Clin Invest doi: 10.1172/JCI114064 contributor: fullname: Cowen – volume: 10 start-page: 150 year: 2019 ident: 2023040500033409300_ article-title: CD73 expression on effector T cells sustained by TGF-β facilitates tumor resistance to anti-4–1BB/CD137 therapy publication-title: Nat Commun doi: 10.1038/s41467-018-08123-8 contributor: fullname: Chen – volume: 13 start-page: 913 year: 2007 ident: 2023040500033409300_ article-title: Extracellular ATP triggers and maintains asthmatic airway inflammation by activating dendritic cells publication-title: Nat Med doi: 10.1038/nm1617 contributor: fullname: Idzko – volume: 531 start-page: 47 year: 2016 ident: 2023040500033409300_ article-title: Genomic analyses identify molecular subtypes of pancreatic cancer publication-title: Nature doi: 10.1038/nature16965 contributor: fullname: Bailey – volume: 35 start-page: 4282 year: 2016 ident: 2023040500033409300_ article-title: p53 mutations cooperate with oncogenic Kras to promote adenocarcinoma from pancreatic ductal cells publication-title: Oncogene doi: 10.1038/onc.2015.441 contributor: fullname: Bailey – volume: 2015 start-page: 558 year: 2015 ident: 2023040500033409300_ article-title: Culturing primary mouse pancreatic ductal cells publication-title: Cold Spring Harb Protoc doi: 10.1101/pdb.prot078279 contributor: fullname: Reichert – volume: 11 start-page: 660 year: 2021 ident: 2023040500033409300_ article-title: Cell of origin influences pancreatic cancer subtype publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-20-0633 contributor: fullname: Flowers – volume: 17 start-page: 500 year: 2011 ident: 2023040500033409300_ article-title: Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy publication-title: Nat Med doi: 10.1038/nm.2344 contributor: fullname: Collisson – volume: 509 start-page: 310 year: 2014 ident: 2023040500033409300_ article-title: Nucleotide signalling during inflammation publication-title: Nature doi: 10.1038/nature13085 contributor: fullname: Idzko – volume: 137 start-page: 1072–82, 82.e1–6 year: 2009 ident: 2023040500033409300_ article-title: Ras activity levels control the development of pancreatic diseases publication-title: Gastroenterology doi: 10.1053/j.gastro.2009.05.052 contributor: fullname: Ji – volume: 217 start-page: e20190354 year: 2020 ident: 2023040500033409300_ article-title: Interleukin-17-induced neutrophil extracellular traps mediate resistance to checkpoint blockade in pancreatic cancer publication-title: J Exp Med doi: 10.1084/jem.20190354 contributor: fullname: Zhang – volume: 11 start-page: 56 year: 2023 ident: 2023040500033409300_ article-title: CD73 inhibits cGAS-STING and cooperates with CD39 to promote pancreatic cancer publication-title: Cancer Immunol Res doi: 10.1158/2326-6066.CIR-22-0260 contributor: fullname: Jacoberger-Foissac – volume: 32 start-page: 185 year: 2017 ident: 2023040500033409300_ article-title: Electronic address aadhe, cancer genome atlas research n. integrated genomic characterization of pancreatic ductal adenocarcinoma publication-title: Cancer Cell doi: 10.1016/j.ccell.2017.07.007 contributor: fullname: Cancer Genome Atlas Research Network – volume: 67 start-page: 3970 year: 2007 ident: 2023040500033409300_ article-title: Specific growth rate versus doubling time for quantitative characterization of tumor growth rate publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-06-3822 contributor: fullname: Mehrara – volume: 68 start-page: 467 year: 2019 ident: 2023040500033409300_ article-title: CD73 expression in normal and pathological human hepatobiliopancreatic tissues publication-title: Cancer Immunol Immunother doi: 10.1007/s00262-018-2290-1 contributor: fullname: Sciarra – volume: 17 start-page: 487 year: 2020 ident: 2023040500033409300_ article-title: Pancreatic cancer stroma: an update on therapeutic targeting strategies publication-title: Nat Rev Gastroenterol Hepatol doi: 10.1038/s41575-020-0300-1 contributor: fullname: Hosein – volume: 14 start-page: 7 year: 2013 ident: 2023040500033409300_ article-title: GSVA: gene set variation analysis for microarray and RNA-seq data publication-title: BMC Bioinf doi: 10.1186/1471-2105-14-7 contributor: fullname: Hänzelmann – volume: 66 start-page: 901 year: 1989 ident: 2023040500033409300_ article-title: P1 and P2 purinergic receptor signal transduction in rat type II pneumocytes publication-title: J Appl Physiol (1985) doi: 10.1152/jappl.1989.66.2.901 contributor: fullname: Warburton – volume: 74 start-page: 7250 year: 2014 ident: 2023040500033409300_ article-title: Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-13-3583 contributor: fullname: Cekic – volume: 13 start-page: 849258 year: 2022 ident: 2023040500033409300_ article-title: Purinergic and adenosinergic signaling in pancreatobiliary diseases publication-title: Front Physiol doi: 10.3389/fphys.2022.849258 contributor: fullname: Faraoni – start-page: 748 volume-title: F1000Res year: 2017 ident: 2023040500033409300_ article-title: CyTOF workflow: differential discovery in high-throughput high-dimensional cytometry datasets contributor: fullname: Nowicka – volume: 110 start-page: 993 year: 2002 ident: 2023040500033409300_ article-title: Ecto-5'-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia publication-title: J Clin Invest doi: 10.1172/JCI0215337 contributor: fullname: Synnestvedt – volume: 8 start-page: 1064 year: 2020 ident: 2023040500033409300_ article-title: The expression of adenosine A2B receptor on antigen-presenting cells suppresses CD8 publication-title: Cancer Immunol Res doi: 10.1158/2326-6066.CIR-19-0833 contributor: fullname: Chen – volume: 11 start-page: R106 year: 2010 ident: 2023040500033409300_ article-title: Differential expression analysis for sequence count data publication-title: Genome Biol doi: 10.1186/gb-2010-11-10-r106 contributor: fullname: Anders – volume: 19 start-page: 3837 year: 2018 ident: 2023040500033409300_ article-title: Targeting adenosine receptor signaling in cancer immunotherapy publication-title: Int J Mol Sci doi: 10.3390/ijms19123837 contributor: fullname: Sek – volume: 41 start-page: 971 year: 2022 ident: 2023040500033409300_ article-title: CD73 induces GM-CSF/MDSC-mediated suppression of T cells to accelerate pancreatic cancer pathogenesis publication-title: Oncogene doi: 10.1038/s41388-021-02132-6 contributor: fullname: King – volume: 11 start-page: OF4 year: 2021 ident: 2023040500033409300_ article-title: Blocking CD73 can shrink pancreatic tumors publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-NB2021-0313 – volume: 9 start-page: 1744946 year: 2020 ident: 2023040500033409300_ article-title: Enhanced expression of CD39 and CD73 on T cells in the regulation of anti-tumor immune responses publication-title: Oncoimmunology doi: 10.1080/2162402X.2020.1744946 contributor: fullname: Shevchenko |
| SSID | ssj0005105 |
| Score | 2.5255618 |
| Snippet | The microenvironment that surrounds pancreatic ductal adenocarcinoma (PDAC) is profoundly desmoplastic and immunosuppressive. Understanding triggers of... Abstract The microenvironment that surrounds pancreatic ductal adenocarcinoma (PDAC) is profoundly desmoplastic and immunosuppressive. Understanding triggers... Ductal-derived pancreatic tumors have elevated epithelial and CD8 + GZM + T-cell CD73 expression that confers sensitivity to small-molecule inhibition of CD73... |
| SourceID | pubmedcentral proquest crossref pubmed |
| SourceType | Open Access Repository Aggregation Database Index Database |
| StartPage | 1111 |
| SubjectTerms | 5'-Nucleotidase - immunology Adenosine Animals Cancer Vaccines Carcinoma, Pancreatic Ductal - pathology Humans Immunosuppression Therapy Immunotherapy Mice Pancreatic Neoplasms - pathology Tumor Biology and Immunology Tumor Microenvironment |
| Title | CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/36720042 https://www.proquest.com/docview/2771636442/abstract/ https://pubmed.ncbi.nlm.nih.gov/PMC10071819 |
| Volume | 83 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbKkBAviDvlJiPxFiUkdhI7j1XLtAEbCDY0nqL40rWiSqeueeGX8fM4viRN1wkxXqLGqRzL58vxOfZ3zkHoLZ0mVSyKBCSgWJhSVYVFDpdEUxUnvODKxlYdHecHp-mHs-xsMPjdYy01axHJX9fGlfyPVKEN5GqiZG8g2a5TaIDfIF-4goTh-k8yHk8YDSe-jK1JhGsyfxuz8dv83BjYNhLK1eEZKZA1EcFkZfPMHpqwkOVlc-F5sJbvOGmkCY38AkCwpqQMxgYTq74B61oCnyNoZg-BHZvDapvFIurtLexXq2ppa0YZffuzCn5E3Y4ODG7m6By1CT7u0QxqZWsfBd_najZv2z_p4OuysSvl54Xhkmgfw-Z3LAi1RJd0SwvzMEtdyZ5IbxQvS11qyVYzuxI3HoGsp2aTVkNrf-vyC-wuBxl3_En3vmg8Og7B-QY3im7Wv_bM_8qy2JEVrZuUcXNMz0vTTQndlISUpptb6DZhRWbc_snhxw25yJNn2zf72DHo5t21o9m2inZcnauM3Z4JdHIf3fO-Cx45ID5AA10_RHeOPDvjETrfxiPu8Ig7PGKPR-zxiB0e8Q4e8bzGDo94g0fs0PcYne6_PxkfhL6QRyjThKzDjMlYyKmOpdLw-SomJKOK8IpmGixYwYVKCNzyjNNEVoUCAyKm6ZTSnBKz1f4E7dXLWj9D2Bz8szjnmoo4nSoiNM3lVKVJmmldCTlEUTuR5YXL11L-VYBD9Kad7hI0qzkuq2q9bC5Lwhg4K-AvkCF66qa_65LmzCgieMK3BNP9wWRt335Sz2c2e7uhJYFZXTy_6UhfoLubr-kl2luvGv0KLOK1eG3B9wfwZLA8 |
| link.rule.ids | 230,315,786,790,891,27957,27958 |
| linkProvider | Flying Publisher |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=CD73-Dependent+Adenosine+Signaling+through+Adora2b+Drives+Immunosuppression+in+Ductal+Pancreatic+Cancer&rft.jtitle=Cancer+research+%28Chicago%2C+Ill.%29&rft.au=Faraoni%2C+Erika+Y.&rft.au=Singh%2C+Kanchan&rft.au=Chandra%2C+Vidhi&rft.au=Le+Roux%2C+Olivereen&rft.date=2023-04-04&rft.issn=0008-5472&rft.eissn=1538-7445&rft.volume=83&rft.issue=7&rft.spage=1111&rft.epage=1127&rft_id=info:doi/10.1158%2F0008-5472.CAN-22-2553&rft.externalDBID=n%2Fa&rft.externalDocID=10_1158_0008_5472_CAN_22_2553 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0008-5472&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0008-5472&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0008-5472&client=summon |